ASX ANNOUNCEMENT

CHANGE OF SHARE REGISTRY

MELBOURNE (AUSTRALIA) 1 July 2024: Invion Limited (ASX: IVX) ("**Invion**" or the "**Company**") advises, in accordance with ASX Listing Rule 3.15.1, that after careful consideration the Company has transferred its provider for shareholder registry services from Link Market Services to Boardroom Pty Limited ("**Boardroom**") effective Monday, 1 July 2024.

Boardroom's contact details are as follows:

Boardroom Pty Limited
Level 8, 210 George Street
Sydney NSW 2000

GPO Box 3993
Sydney NSW 2001

Telephone:	1300 737 760 (in Australia)
	+61 2 9290 9600 (International)
Fax:	1300 653 459 (in Australia)
	+61 2 9279 0664 (International)
Email:	enquiries@boardroomlimited.com.au
Web:	www.boardroomlimited.com.au

The Company's shareholders can easily and efficiently manage their shareholding via Boardroom's user-friendly and secure InvestorServe website portal: www.investorserve.com.au.

This portal provides an online interface to view balances, transaction history, manage communication preferences, submit, and update email addresses, bank account details and tax file numbers, as well as offering a range of other useful functions. Shareholders' most recently notified information will be reflected in the portal. If you have not done so previously, we encourage all shareholders to register for electronic communications.

This announcement was approved for release by the Board of Invion Limited.

Investor and Media enquiries:

Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX).

About Dr.inB

Since 2014, Dr. I&B Co., Ltd. (Dr.inB) has independently developed and commercialized photodynamic therapy (PDT) technology using photoreactive medical materials and laser technology with the goal of "All to Light". Dr.inB develops laser medical devices and pharmaceuticals for the treatment of skin inflammation and tumors, mass-produces high-purity photoreactive raw materials with its own technology, and also develops new patented substances aiming for new drug approval. Dr.inB has relationships with other Korean pharmaceutical companies including Hanlim Pharmaceuticals and Kukjeon Pharmaceuticals. Hanlim Pharmaceuticals have made a strategic investment into Dr.inB following strategic investments from WooGene B&G Co., Ltd. and KST Investment.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".